Arrowhead Pharmaceuticals Q4 2020 Earnings Report
Key Takeaways
Arrowhead Pharmaceuticals reported financial results for its fiscal year ended September 30, 2020. The company earned two $20 million milestone payments from Amgen and signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT.
Earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890.
Hosted a key opinion leader webinar on ARO-ENaC, the company’s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis.
Initiated a Phase 1b study of ARO-HIF2, the company’s first tumor targeted investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma.
Signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT, which includes $300 million upfront.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Forward Guidance
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
Positive Outlook
- Broad portfolio of RNA chemistries
- Efficient modes of delivery
- Therapies trigger the RNA interference mechanism
- Rapid knockdown of target genes
- Durable knockdown of target genes
Challenges Ahead
- Safety and efficacy of product candidates
- Duration and impact of regulatory delays in clinical programs
- Ability to finance operations
- Likelihood and timing of the receipt of future milestone and licensing fees
- Future success of scientific studies